Abstract
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
Keywords: COVID-19 vaccine; Omicron variant; SARS-CoV-2; anti-N antibodies; natural immunity; sero-epidemiological survey.
All Keywords
【저자키워드】 SARS-CoV-2, COVID-19 vaccine, anti-N antibodies, Omicron variant, natural immunity, sero-epidemiological survey., 【초록키워드】 COVID-19, Immunity, antibody, omicron, Spain, incidence, Anti-spike, hybrid, COVID-19 cases, adjusted odds ratio, 95% confidence interval, anti-S antibody, anti-N antibody, 【제목키워드】 antibody, Seroprevalence, Spain, risk of COVID-19,
【저자키워드】 SARS-CoV-2, COVID-19 vaccine, anti-N antibodies, Omicron variant, natural immunity, sero-epidemiological survey., 【초록키워드】 COVID-19, Immunity, antibody, omicron, Spain, incidence, Anti-spike, hybrid, COVID-19 cases, adjusted odds ratio, 95% confidence interval, anti-S antibody, anti-N antibody, 【제목키워드】 antibody, Seroprevalence, Spain, risk of COVID-19,